Metoclopramide Injection

Generic name: Pronounced as (met oh kloe pra' mide)
Brand names
  • Reglan® I.V.
Click on drug name to hear pronunciation

Medical Content Reviewed By HelloPharmacist Staff

Last Revised - 10/15/2018

Receiving metoclopramide injection may cause you to develop a muscle problem called tardive dyskinesia. If you develop tardive dyskinesia, you will move your muscles, especially the muscles in your face in unusual ways. You will not be able to control or stop these movements. Tardive dyskinesia may not go away even after you stop receiving metoclopramide injection. The longer you receive metoclopramide injection, the greater the risk that you will develop tardive dyskinesia. Therefore, your doctor will probably tell you not to receive metoclopramide injection for longer than 12 weeks. The risk that you will develop tardive dyskinesia is also greater if you are taking medications for mental illness, if you have diabetes, or if you are elderly, especially if you are a woman. Call your doctor immediately if you develop any uncontrollable body movements, especially lip smacking, mouth puckering, chewing, frowning, scowling, sticking out your tongue, blinking, eye movements, or shaking arms or legs.

Your doctor or pharmacist will give you the manufacturer's patient information sheet (Medication Guide) when you begin treatment with metoclopramide injection and each time you refill your prescription. Read the information carefully and ask your doctor or pharmacist if you have any questions. You can also visit the Food and Drug Administration (FDA) website (http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm) to obtain the Medication Guide.

Talk to your doctor about the risk of receiving metoclopramide injection.

Metoclopramide injection is used to relieve symptoms caused by slow stomach emptying in people who have diabetes. These symptoms include nausea, vomiting, heartburn, loss of appetite, and feeling of fullness that lasts long after meals. Metoclopramide injection is also used to prevent nausea and vomiting caused by chemotherapy or that may occur after surgery. Metoclopramide injection is also sometimes used to empty the intestines during certain medical procedures. Metoclopramide injection is in a class of medications called prokinetic agents. It works by speeding the movement of food through the stomach and intestines.

Metoclopramide injection comes as a liquid to be injected into a muscle or into a vein. When metoclopramide injection is used to treat slowed stomach emptying due to diabetes, it may be given up to four times a day. When metoclopramide injection is used to prevent nausea and vomiting due to chemotherapy, it is usually given 30 minutes before the chemotherapy, then once every 2 hours for two doses, then once every 3 hours for three doses. Metoclopramide injection is also sometimes given during surgery. If you are injecting metoclopramide injection at home, inject it at around the same times every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Use metoclopramide injection exactly as directed. Do not inject more or less of it or inject it more often than prescribed by your doctor.

Metoclopramide injection is also sometimes used to relieve nausea and vomiting caused by migraine headaches. Talk to your doctor about the risks of using this medication for your condition.

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

Before receiving metoclopramide injection,

  • tell your doctor and pharmacist if you are allergic to metoclopramide injection, any other medications, or any of the ingredients in metoclopramide injection. Ask your pharmacist for a list of the ingredients.

  • tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements and herbal products you are taking or plan to take. Be sure to mention any of the following: acetaminophen (Tylenol, others); antihistamines; digoxin (Lanoxicaps, Lanoxin); cyclosporine (Gengraf, Neoral, Sandimmune); insulin; ipratropium (Atrovent); levodopa (in Sinemet, in Stalevo); medications for irritable bowel disease, motion sickness, Parkinson's disease, ulcers, or urinary problems; monoamine oxidase (MAO) inhibitors, including isocarboxazid (Marplan), phenelzine (Nardil), selegiline (Eldepryl, Emsam, Zelapar), and tranylcypromine (Parnate); narcotic medications for pain; sedatives; sleeping pills; tetracycline (Bristacycline, Sumycin); tranquilizers. Your doctor may need to change the doses of your medications or monitor you more carefully for side effects.

  • tell your doctor if you have or have ever had blockage or bleeding in your stomach or intestines, pheochromocytoma (tumor on a small gland near the kidneys); or seizures. Your doctor will probably tell you not to take metoclopramide.

  • tell your doctor if you have or have ever had Parkinson's disease (PD; a disorder of the nervous system that causes difficulties with movement, muscle control, and balance); high blood pressure; depression; breast cancer; asthma;glucose-6-phosphate dehydrogenase (G-6PD) deficiency (an inherited blood disorder); NADH cytochrome B5 reductase deficiency (an inherited blood disorder); or heart, liver, or kidney disease.

  • tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. If you become pregnant while receiving metoclopramide injection, call your doctor.

  • talk to your doctor about the risks and benefits of receiving metoclopramide injection if you are 65 years of age or older. Older adults should not usually receive metoclopramide injection, unless it is used to treat slow stomach emptying, because it is not as safe or effective as other medications that can be used to treat those conditions.

  • you should know that metoclopramide injection may make you drowsy. Do not drive a car or operate machinery until you know how this medication affects you.

  • ask your doctor about the safe use of alcoholic beverages while you are receiving metoclopramide injection. Alcohol can make the side effects from metoclopramide injection worse.

Unless your doctor tells you otherwise, continue your normal diet.

If you are injecting metoclopramide injection at home, inject the missed dose as soon as you remember it. However, if it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule. Do not inject a double dose to make up for a missed one.

  • Metoclopramide injection may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

    • drowsiness

    • excessive tiredness

    • weakness

    • headache

    • dizziness

    • restlessness

    • nervousness or jitteriness

    • agitation

    • difficulty falling asleep or staying asleep

    • pacing

    • foot tapping

    • slow or stiff movements

    • blank facial expression

    • diarrhea

    • nausea

    • breast enlargement or discharge

    • missed menstrual period

    • decreased sexual ability

    • frequent urination

    • urinary incontinence

    • flushing

  • Some side effects can be serious. If you experience any of these symptoms or those listed in the IMPORTANT WARNING section, call your doctor immediately:

    • tightening of the muscles, especially in the jaw or neck

    • speech problems

    • depression

    • thinking about harming or killing yourself

    • fever

    • muscle stiffness

    • confusion

    • fast, slow, or irregular heartbeat

    • sweating

    • seizures

    • rash

    • hives

    • swelling of the eyes, face, lips, tongue, mouth, throat, arms, hands, feet, ankles, or lower legs

    • difficulty breathing or swallowing

    • high-pitched sounds while breathing

    • vision problems

  • Metoclopramide injection may cause other side effects. Call your doctor if you have any unusual problems while receiving this medication.

  • If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

Your healthcare provider will tell you how to store your medication. Store your medication only as directed. Make sure you understand how to store your medication properly.

Keep your supplies in a clean, dry place that is out of the reach of children when you are not using them. Your healthcare provider will tell you how to dispose of used needles, syringes, tubing, and containers to avoid accidental injury.

Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA's Safe Disposal of Medicines website (http://goo.gl/c4Rm4p) for more information if you do not have access to a take-back program.

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

Symptoms of overdose may include the following:

  • drowsiness

  • confusion

  • unusual, uncontrollable movements

Keep all appointments with your doctor.

Do not let anyone else use your medication. Ask your pharmacist if you have any questions about refilling your prescription.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

Drug Interaction
Moxifloxacin Moxifloxacin The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Moxifloxacin.
Montelukast Montelukast The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Montelukast is combined with Metoclopramide.
Insulin Glargine (rDNA origin) Injection Insulin Glargine (rDNA origin) Injection The therapeutic efficacy of Metoclopramide can be increased when used in combination with Insulin glargine.
Leflunomide Leflunomide The serum concentration of Metoclopramide can be decreased when it is combined with Leflunomide.
Delavirdine Delavirdine The metabolism of Metoclopramide can be decreased when combined with Delavirdine.
Nevirapine Nevirapine The metabolism of Nevirapine can be decreased when combined with Metoclopramide.
Atorvastatin Atorvastatin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Atorvastatin is combined with Metoclopramide.
Dolasetron Dolasetron The risk or severity of sedation can be increased when Metoclopramide is combined with Dolasetron.
Alendronate Alendronate The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Metoclopramide.
Aminophylline Aminophylline The metabolism of Metoclopramide can be decreased when combined with Aminophylline.
Anagrelide Anagrelide The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Anagrelide.
Cilostazol Cilostazol The metabolism of Cilostazol can be decreased when combined with Metoclopramide.
Clopidogrel Clopidogrel The metabolism of Metoclopramide can be decreased when combined with Clopidogrel.
Diphenoxylate Diphenoxylate The risk or severity of sedation can be increased when Metoclopramide is combined with Diphenoxylate.
Erythromycin and Sulfisoxazole Erythromycin and Sulfisoxazole The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Erythromycin.
Estrogen and Progestin (Oral Contraceptives) Estrogen and Progestin (Oral Contraceptives) The metabolism of Metoclopramide can be decreased when combined with Conjugated estrogens.
Fenofibrate Fenofibrate The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Fenofibrate is combined with Metoclopramide.
Guanfacine Guanfacine The risk or severity of sedation can be increased when Guanfacine is combined with Metoclopramide.
Magnesium Hydroxide Magnesium Hydroxide Metoclopramide may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.
Mycophenolate Mycophenolate Mycophenolic acid may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Nafarelin Nafarelin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nafarelin is combined with Metoclopramide.
Naratriptan Naratriptan The risk or severity of sedation can be increased when Naratriptan is combined with Metoclopramide.
Olsalazine Olsalazine Olsalazine may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Paregoric Paregoric The therapeutic efficacy of Morphine can be decreased when used in combination with Metoclopramide.
Penbutolol Penbutolol The metabolism of Metoclopramide can be decreased when combined with Acebutolol.
Pentazocine Pentazocine The therapeutic efficacy of Pentazocine can be decreased when used in combination with Metoclopramide.
Potassium Potassium Potassium may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.
Prednisone Prednisone The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Prednisone.
Ranitidine Ranitidine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ranitidine is combined with Metoclopramide.
Reserpine Reserpine The risk or severity of adverse effects can be increased when Metoclopramide is combined with Reserpine.
Rizatriptan Rizatriptan The risk or severity of sedation can be increased when Rizatriptan is combined with Metoclopramide.
Sumatriptan Sumatriptan The risk or severity of sedation can be increased when Sumatriptan is combined with Metoclopramide.
Tacrolimus Tacrolimus Tacrolimus may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Tizanidine Tizanidine The risk or severity of sedation can be increased when Tizanidine is combined with Metoclopramide.
Triamcinolone Triamcinolone The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Triamcinolone.
Zolmitriptan Zolmitriptan The risk or severity of sedation can be increased when Zolmitriptan is combined with Metoclopramide.
Ampicillin Injection Ampicillin Injection Ampicillin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Doxycycline Injection Doxycycline Injection Doxycycline may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Famotidine Injection Famotidine Injection The risk or severity of QTc prolongation can be increased when Famotidine is combined with Metoclopramide.
Fluconazole Injection Fluconazole Injection The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Metoclopramide.
Foscarnet Injection Foscarnet Injection Foscarnet may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Hydromorphone Injection Hydromorphone Injection The therapeutic efficacy of Hydromorphone can be decreased when used in combination with Metoclopramide.
Interferon Beta-1b Injection Interferon Beta-1b Injection The metabolism of Metoclopramide can be decreased when combined with Interferon beta-1b.
Interferon Gamma-1b Injection Interferon Gamma-1b Injection The metabolism of Metoclopramide can be decreased when combined with Interferon gamma-1b.
Levofloxacin Injection Levofloxacin Injection The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Levofloxacin.
Meperidine Injection Meperidine Injection The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Meperidine.
Methylprednisolone Injection Methylprednisolone Injection The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Methylprednisolone.
Metronidazole Injection Metronidazole Injection The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Metoclopramide.
Morphine Injection Morphine Injection The therapeutic efficacy of Morphine can be decreased when used in combination with Metoclopramide.
Pamidronate Injection Pamidronate Injection Pamidronic acid may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Vancomycin Injection Vancomycin Injection Metoclopramide may decrease the excretion rate of Vancomycin which could result in a higher serum level.
Zidovudine Injection Zidovudine Injection The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Zidovudine is combined with Metoclopramide.
Altretamine Altretamine The risk or severity of adverse effects can be increased when Metoclopramide is combined with Amphetamine.
Cefuroxime Cefuroxime Cefuroxime may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Cyclosporine Cyclosporine Metoclopramide can cause an increase in the absorption of Cyclosporine resulting in an increased serum concentration and potentially a worsening of adverse effects.
Ondansetron Ondansetron The risk or severity of sedation can be increased when Metoclopramide is combined with Ondansetron.
Granisetron Granisetron The risk or severity of sedation can be increased when Granisetron is combined with Metoclopramide.
Torsemide Torsemide Torasemide may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.
Olanzapine Olanzapine The risk or severity of adverse effects can be increased when Metoclopramide is combined with Olanzapine.
Alosetron Alosetron The risk or severity of sedation can be increased when Alosetron is combined with Metoclopramide.
Dofetilide Dofetilide The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Dofetilide.
Entacapone Entacapone The risk or severity of sedation can be increased when Metoclopramide is combined with Entacapone.
Eprosartan Eprosartan The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Eprosartan is combined with Metoclopramide.
Hydroxychloroquine Hydroxychloroquine The metabolism of Metoclopramide can be decreased when combined with Hydroxychloroquine.
Meloxicam Meloxicam Meloxicam may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Oxcarbazepine Oxcarbazepine The risk or severity of sedation can be increased when Metoclopramide is combined with Oxcarbazepine.
Pantoprazole Pantoprazole Pantoprazole may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Risedronate Risedronate The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Risedronic acid is combined with Metoclopramide.
Temozolomide Temozolomide Temozolomide may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Zaleplon Zaleplon The risk or severity of sedation can be increased when Zaleplon is combined with Metoclopramide.
Anakinra Anakinra The metabolism of Metoclopramide can be increased when combined with Anakinra.
Desloratadine Desloratadine The risk or severity of sedation can be increased when Metoclopramide is combined with Desloratadine.
Linezolid Linezolid The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Metoclopramide.
Rivastigmine Rivastigmine The risk or severity of adverse effects can be increased when Rivastigmine is combined with Metoclopramide.
Trimipramine Trimipramine The risk or severity of sedation can be increased when Metoclopramide is combined with Trimipramine.
Etanercept Injection Etanercept Injection The metabolism of Metoclopramide can be increased when combined with Etanercept.
Glycopyrrolate Glycopyrrolate The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Metoclopramide.
Modafinil Modafinil The metabolism of Metoclopramide can be increased when combined with Modafinil.
Perindopril Perindopril Perindopril may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Tenofovir Tenofovir Tenofovir may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Choline Magnesium Trisalicylate Choline Magnesium Trisalicylate Choline magnesium trisalicylate may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Eplerenone Eplerenone Eplerenone may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.
Escitalopram Escitalopram The risk or severity of sedation can be increased when Metoclopramide is combined with Escitalopram.
Zonisamide Zonisamide The risk or severity of sedation can be increased when Zonisamide is combined with Metoclopramide.
Adalimumab Injection Adalimumab Injection The metabolism of Metoclopramide can be increased when combined with Adalimumab.
Aripiprazole Aripiprazole The risk or severity of adverse effects can be increased when Metoclopramide is combined with Aripiprazole.
Atomoxetine Atomoxetine The metabolism of Atomoxetine can be decreased when combined with Metoclopramide.
Dexmethylphenidate Dexmethylphenidate The risk or severity of sedation can be increased when Dexmethylphenidate is combined with Metoclopramide.
Teriparatide Injection Teriparatide Injection The therapeutic efficacy of Teriparatide can be decreased when used in combination with Metoclopramide.
Atazanavir Atazanavir Atazanavir may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Almotriptan Almotriptan The risk or severity of sedation can be increased when Almotriptan is combined with Metoclopramide.
Eletriptan Eletriptan The risk or severity of sedation can be increased when Eletriptan is combined with Metoclopramide.
Mefloquine Mefloquine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Mefloquine is combined with Metoclopramide.
Rosuvastatin Rosuvastatin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Rosuvastatin is combined with Metoclopramide.
Vardenafil Vardenafil The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Metoclopramide.
Alfuzosin Alfuzosin The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Metoclopramide.
Emtricitabine Emtricitabine Emtricitabine may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Interferon Beta-1a Subcutaneous Injection Interferon Beta-1a Subcutaneous Injection The metabolism of Metoclopramide can be decreased when combined with Interferon beta-1a.
Memantine Memantine The therapeutic efficacy of Memantine can be decreased when used in combination with Metoclopramide.
Tegaserod Tegaserod The metabolism of Metoclopramide can be decreased when combined with Tegaserod.
Tadalafil Tadalafil Tadalafil may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Frovatriptan Frovatriptan The risk or severity of sedation can be increased when Frovatriptan is combined with Metoclopramide.
Gemifloxacin Gemifloxacin The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Gemifloxacin.
Progesterone Progesterone The metabolism of Progesterone can be decreased when combined with Metoclopramide.
Apomorphine Injection Apomorphine Injection The risk or severity of sedation can be increased when Metoclopramide is combined with Apomorphine.
Infliximab Injection Infliximab Injection The metabolism of Metoclopramide can be increased when combined with Infliximab.
Protriptyline Protriptyline The risk or severity of sedation can be increased when Metoclopramide is combined with Protriptyline.
Duloxetine Duloxetine The risk or severity of adverse effects can be increased when Metoclopramide is combined with Duloxetine.
Tinidazole Tinidazole Tinidazole may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Trospium Trospium The therapeutic efficacy of Trospium can be decreased when used in combination with Metoclopramide.
Cefditoren Cefditoren Cefdinir may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Cinacalcet Cinacalcet The metabolism of Metoclopramide can be decreased when combined with Cinacalcet.
Cyanocobalamin Injection Cyanocobalamin Injection Hydroxocobalamin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Erlotinib Erlotinib The metabolism of Erlotinib can be decreased when combined with Metoclopramide.
Eszopiclone Eszopiclone The risk or severity of sedation can be increased when Eszopiclone is combined with Metoclopramide.
Ganciclovir Ganciclovir The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ganciclovir is combined with Metoclopramide.
Insulin Aspart (rDNA Origin) Injection Insulin Aspart (rDNA Origin) Injection The therapeutic efficacy of Metoclopramide can be increased when used in combination with Insulin aspart.
Ribavirin Ribavirin Ribavirin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Solifenacin Solifenacin The therapeutic efficacy of Solifenacin can be decreased when used in combination with Metoclopramide.
Valganciclovir Valganciclovir Metoclopramide may decrease the excretion rate of Valganciclovir which could result in a higher serum level.
Voriconazole Voriconazole The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Metoclopramide.
Adefovir Adefovir Adefovir may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Dextroamphetamine Dextroamphetamine The risk or severity of adverse effects can be increased when Metoclopramide is combined with Amphetamine.
Entecavir Entecavir The metabolism of Metoclopramide can be decreased when combined with Entecavir.
Peginterferon Alfa-2a Injection Peginterferon Alfa-2a Injection The metabolism of Metoclopramide can be decreased when combined with Peginterferon alfa-2a.
Peginterferon Alfa-2b (PEG-Intron) Peginterferon Alfa-2b (PEG-Intron) The serum concentration of Metoclopramide can be increased when it is combined with Peginterferon alfa-2b.
Sodium Oxybate Sodium Oxybate The risk or severity of sedation can be increased when Metoclopramide is combined with Sodium oxybate.
Ibandronate Ibandronate The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Metoclopramide.
Isocarboxazid Isocarboxazid The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Metoclopramide.
Ramelteon Ramelteon The risk or severity of sedation can be increased when Ramelteon is combined with Metoclopramide.
Darifenacin Darifenacin The therapeutic efficacy of Darifenacin can be decreased when used in combination with Metoclopramide.
Fentanyl Fentanyl The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Fentanyl.
Pregabalin Pregabalin The risk or severity of sedation can be increased when Pregabalin is combined with Metoclopramide.
Deferasirox Deferasirox The serum concentration of Metoclopramide can be increased when it is combined with Deferasirox.
Phenylephrine Phenylephrine The metabolism of Metoclopramide can be increased when combined with Phenylephrine.
Tipranavir Tipranavir The metabolism of Metoclopramide can be decreased when combined with Tipranavir.
Felbamate Felbamate The risk or severity of sedation can be increased when Felbamate is combined with Metoclopramide.
Insulin Detemir (rDNA Origin) Injection Insulin Detemir (rDNA Origin) Injection The therapeutic efficacy of Metoclopramide can be increased when used in combination with Insulin detemir.
Ranolazine Ranolazine The serum concentration of Ranolazine can be increased when it is combined with Metoclopramide.
Abatacept Injection Abatacept Injection The metabolism of Metoclopramide can be increased when combined with Abatacept.
Rasagiline Rasagiline The risk or severity of sedation can be increased when Metoclopramide is combined with Rasagiline.
Imatinib Imatinib The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Imatinib.
Sitagliptin Sitagliptin Metoclopramide may decrease the excretion rate of Sitagliptin which could result in a higher serum level.
Varenicline Varenicline Metoclopramide may decrease the excretion rate of Varenicline which could result in a higher serum level.
Gefitinib Gefitinib The metabolism of Gefitinib can be decreased when combined with Metoclopramide.
Albuterol Albuterol The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Metoclopramide.
Paliperidone Paliperidone The risk or severity of adverse effects can be increased when Metoclopramide is combined with Paliperidone.
Bortezomib Bortezomib The metabolism of Bortezomib can be decreased when combined with Metoclopramide.
Clofarabine Injection Clofarabine Injection Clofarabine may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Insulin Glulisine (rDNA origin) Injection Insulin Glulisine (rDNA origin) Injection The therapeutic efficacy of Metoclopramide can be increased when used in combination with Insulin glulisine.
Lubiprostone Lubiprostone Lubiprostone may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Oxaliplatin Injection Oxaliplatin Injection The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Oxaliplatin.
Posaconazole Posaconazole The serum concentration of Posaconazole can be decreased when it is combined with Metoclopramide.
Primaquine Primaquine The metabolism of Primaquine can be decreased when combined with Metoclopramide.
Pemetrexed Injection Pemetrexed Injection Metoclopramide may decrease the excretion rate of Pemetrexed which could result in a higher serum level.
Dimenhydrinate Dimenhydrinate The risk or severity of sedation can be increased when Metoclopramide is combined with Dimenhydrinate.
Lisdexamfetamine Lisdexamfetamine The metabolism of Lisdexamfetamine can be decreased when combined with Metoclopramide.
Nabilone Nabilone The risk or severity of sedation can be increased when Metoclopramide is combined with Nabilone.
Vorinostat Vorinostat The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Vorinostat.
Sorafenib Sorafenib The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Metoclopramide.
Sunitinib Sunitinib The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Sunitinib.
Dronabinol Dronabinol The risk or severity of sedation can be increased when Dronabinol is combined with Metoclopramide.
Lapatinib Lapatinib The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Lapatinib.
Levocetirizine Levocetirizine The risk or severity of sedation can be increased when Metoclopramide is combined with Levocetirizine.
Pegaptanib Injection Pegaptanib Injection Metoclopramide may decrease the excretion rate of Pegaptanib which could result in a higher serum level.
Dasatinib Dasatinib The metabolism of Dasatinib can be decreased when combined with Metoclopramide.
Mexiletine Mexiletine The metabolism of Mexiletine can be decreased when combined with Metoclopramide.
Armodafinil Armodafinil The metabolism of Metoclopramide can be increased when combined with Armodafinil.
Azacitidine Injection Azacitidine Injection Azacitidine may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Ivermectin Ivermectin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ivermectin is combined with Metoclopramide.
Temsirolimus Temsirolimus The metabolism of Metoclopramide can be decreased when combined with Temsirolimus.
Antipyrine-Benzocaine Otic Antipyrine-Benzocaine Otic The risk or severity of methemoglobinemia can be increased when Benzocaine is combined with Metoclopramide.
Lenalidomide Lenalidomide Lenalidomide may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Nilotinib Nilotinib The metabolism of Nilotinib can be decreased when combined with Metoclopramide.
Toremifene Toremifene The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Toremifene.
Raltegravir Raltegravir The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Metoclopramide is combined with Raltegravir.
Budesonide Budesonide The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Budesonide.
Desmopressin Desmopressin Desmopressin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
OnabotulinumtoxinA Injection OnabotulinumtoxinA Injection The risk or severity of sedation can be increased when Metoclopramide is combined with Botulinum toxin type A.
RimabotulinumtoxinB Injection RimabotulinumtoxinB Injection The risk or severity of sedation can be increased when Metoclopramide is combined with Botulinum Toxin Type B.
Doripenem Injection Doripenem Injection Metoclopramide may decrease the excretion rate of Doripenem which could result in a higher serum level.
Arsenic Trioxide Injection Arsenic Trioxide Injection The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Arsenic trioxide.
Desvenlafaxine Desvenlafaxine The risk or severity of adverse effects can be increased when Metoclopramide is combined with Desvenlafaxine.
Cevimeline Cevimeline The metabolism of Cevimeline can be decreased when combined with Metoclopramide.
Nebivolol Nebivolol The metabolism of Nebivolol can be decreased when combined with Metoclopramide.
Bendamustine Injection Bendamustine Injection The metabolism of Bendamustine can be decreased when combined with Metoclopramide.
Pilocarpine Pilocarpine The risk or severity of adverse effects can be increased when Metoclopramide is combined with Pilocarpine.
Flecainide Flecainide The metabolism of Flecainide can be decreased when combined with Metoclopramide.
Certolizumab Injection Certolizumab Injection The metabolism of Metoclopramide can be increased when combined with Certolizumab pegol.
Irinotecan Injection Irinotecan Injection Metoclopramide may increase the neuromuscular blocking activities of Irinotecan.
Daptomycin Injection Daptomycin Injection The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Metoclopramide.
Praziquantel Praziquantel The metabolism of Metoclopramide can be decreased when combined with Praziquantel.
Methylnaltrexone Injection Methylnaltrexone Injection Metoclopramide may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.
Rufinamide Rufinamide The risk or severity of sedation can be increased when Metoclopramide is combined with Rufinamide.
Midazolam Midazolam The risk or severity of sedation can be increased when Midazolam is combined with Metoclopramide.
Naltrexone Injection Naltrexone Injection The therapeutic efficacy of Naltrexone can be increased when used in combination with Metoclopramide.
Dexrazoxane Injection Dexrazoxane Injection Dexrazoxane may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Eltrombopag Eltrombopag The metabolism of Eltrombopag can be decreased when combined with Metoclopramide.
Milnacipran Milnacipran The risk or severity of adverse effects can be increased when Metoclopramide is combined with Milnacipran.
Plerixafor Injection Plerixafor Injection Metoclopramide may decrease the excretion rate of Plerixafor which could result in a higher serum level.
Fesoterodine Fesoterodine The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Metoclopramide.
Degarelix Injection Degarelix Injection The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Degarelix.
Betaxolol Betaxolol The metabolism of Betaxolol can be decreased when combined with Metoclopramide.
Iloperidone Iloperidone The risk or severity of adverse effects can be increased when Metoclopramide is combined with Iloperidone.
Prasugrel Prasugrel Metoclopramide may decrease the excretion rate of Prasugrel which could result in a higher serum level.
Lacosamide Lacosamide The risk or severity of sedation can be increased when Metoclopramide is combined with Lacosamide.
Everolimus Everolimus The metabolism of Metoclopramide can be decreased when combined with Everolimus.
Tolvaptan (low blood sodium) Tolvaptan (low blood sodium) Tolvaptan may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.
Dronedarone Dronedarone The metabolism of Metoclopramide can be decreased when combined with Dronedarone.
AbobotulinumtoxinA Injection AbobotulinumtoxinA Injection The risk or severity of sedation can be increased when Metoclopramide is combined with Botulinum toxin type A.
Pralatrexate Injection Pralatrexate Injection Metoclopramide may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Palonosetron Injection Palonosetron Injection The risk or severity of sedation can be increased when Metoclopramide is combined with Palonosetron.
Saxagliptin Saxagliptin Metoclopramide may decrease the excretion rate of Saxagliptin which could result in a higher serum level.
Telavancin Injection Telavancin Injection The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Telavancin.
Romidepsin Injection Romidepsin Injection The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Romidepsin.
Tapentadol Tapentadol The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Tapentadol.
Topotecan Topotecan Topotecan may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Golimumab Injection Golimumab Injection The metabolism of Metoclopramide can be increased when combined with Golimumab.
Pazopanib Pazopanib The metabolism of Pazopanib can be decreased when combined with Metoclopramide.
Asenapine Asenapine The risk or severity of adverse effects can be increased when Metoclopramide is combined with Asenapine.
Vigabatrin Vigabatrin The risk or severity of sedation can be increased when Metoclopramide is combined with Vigabatrin.
Pitavastatin Pitavastatin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Metoclopramide is combined with Pitavastatin.
Albendazole Albendazole The metabolism of Metoclopramide can be decreased when combined with Albendazole.
Oxymorphone Oxymorphone The therapeutic efficacy of Oxymorphone can be decreased when used in combination with Metoclopramide.
Tocilizumab Injection Tocilizumab Injection The metabolism of Metoclopramide can be increased when combined with Tocilizumab.
Dalfampridine Dalfampridine Metoclopramide may decrease the excretion rate of Dalfampridine which could result in a higher serum level.
Eribulin Injection Eribulin Injection The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Eribulin.
IncobotulinumtoxinA Injection IncobotulinumtoxinA Injection The risk or severity of sedation can be increased when Metoclopramide is combined with Botulinum toxin type A.
Ceftaroline Injection Ceftaroline Injection Ceftaroline fosamil may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Lurasidone Lurasidone The risk or severity of adverse effects can be increased when Metoclopramide is combined with Lurasidone.
Acetaminophen Injection Acetaminophen Injection The risk or severity of methemoglobinemia can be increased when Metoclopramide is combined with Acetaminophen.
Vilazodone Vilazodone The risk or severity of sedation can be increased when Vilazodone is combined with Metoclopramide.
Ipilimumab Injection Ipilimumab Injection Metoclopramide may decrease the excretion rate of Ipilimumab which could result in a higher serum level.
Denileukin Diftitox Injection Denileukin Diftitox Injection Aldesleukin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Terbutaline Injection Terbutaline Injection The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Metoclopramide.
Roflumilast Roflumilast Metoclopramide may decrease the excretion rate of Roflumilast which could result in a higher serum level.
Rilpivirine Rilpivirine The metabolism of Metoclopramide can be decreased when combined with Rilpivirine.
Potassium Iodide Potassium Iodide The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Metoclopramide.
Cyclophosphamide Injection Cyclophosphamide Injection The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Metoclopramide.
Abiraterone Abiraterone The serum concentration of Metoclopramide can be increased when it is combined with Abiraterone.
Triptorelin Injection Triptorelin Injection The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Triptorelin.
Rivaroxaban Rivaroxaban Metoclopramide may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.
Ruxolitinib Ruxolitinib Metoclopramide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Vandetanib Vandetanib The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Vandetanib.
Clobazam Clobazam The risk or severity of sedation can be increased when Clobazam is combined with Metoclopramide.
Vemurafenib Vemurafenib The serum concentration of Vemurafenib can be increased when it is combined with Metoclopramide.
Deferiprone Deferiprone Metoclopramide may decrease the excretion rate of Deferiprone which could result in a higher serum level.
Axitinib Axitinib The metabolism of Axitinib can be decreased when combined with Metoclopramide.
Crizotinib Crizotinib The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Crizotinib.
Cabergoline Cabergoline The risk or severity of sedation can be increased when Metoclopramide is combined with Cabergoline.
Naloxone Injection Naloxone Injection Naloxone may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Fondaparinux Injection Fondaparinux Injection Fondaparinux may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Ezogabine Ezogabine The risk or severity of sedation can be increased when Metoclopramide is combined with Tiagabine.
Iloprost Iloprost The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Iloprost is combined with Metoclopramide.
Enzalutamide Enzalutamide Metoclopramide may decrease the excretion rate of Enzalutamide which could result in a higher serum level.
Mirabegron Mirabegron The metabolism of Metoclopramide can be decreased when combined with Mirabegron.
Corticotropin, Repository Injection Corticotropin, Repository Injection The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Corticotropin.
Teriflunomide Teriflunomide The serum concentration of Metoclopramide can be decreased when it is combined with Teriflunomide.
Teduglutide Injection Teduglutide Injection Metoclopramide may decrease the excretion rate of Teduglutide which could result in a higher serum level.
Bedaquiline Bedaquiline The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Bedaquiline.
Alogliptin Alogliptin The metabolism of Alogliptin can be decreased when combined with Metoclopramide.
Ponatinib Ponatinib The metabolism of Ponatinib can be decreased when combined with Metoclopramide.
Pomalidomide Pomalidomide The risk or severity of sedation can be increased when Metoclopramide is combined with Pomalidomide.
Canagliflozin Canagliflozin Metoclopramide may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Methazolamide Methazolamide Methazolamide may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.
Dabrafenib Dabrafenib The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Dabrafenib.
Ospemifene Ospemifene The metabolism of Metoclopramide can be decreased when combined with Ospemifene.
Trametinib Trametinib Metoclopramide may decrease the excretion rate of Trametinib which could result in a higher serum level.
Levomilnacipran Levomilnacipran The risk or severity of adverse effects can be increased when Metoclopramide is combined with Levomilnacipran.
Ertapenem Injection Ertapenem Injection Ertapenem may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Vortioxetine Vortioxetine The risk or severity of sedation can be increased when Metoclopramide is combined with Vortioxetine.
Perampanel Perampanel The risk or severity of sedation can be increased when Metoclopramide is combined with Perampanel.
Ibrutinib Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Metoclopramide.
Ketorolac Injection Ketorolac Injection Ketorolac may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Simeprevir Simeprevir The metabolism of Metoclopramide can be decreased when combined with Simeprevir.
Sofosbuvir Sofosbuvir Metoclopramide may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.
Dapagliflozin Dapagliflozin The metabolism of Dapagliflozin can be decreased when combined with Metoclopramide.
Apremilast Apremilast The metabolism of Metoclopramide can be increased when combined with Apremilast.
Droxidopa Droxidopa Metoclopramide may decrease the excretion rate of Droxidopa which could result in a higher serum level.
Ceritinib Ceritinib The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Ceritinib.
Siltuximab Injection Siltuximab Injection The metabolism of Metoclopramide can be increased when combined with Siltuximab.
Eslicarbazepine Eslicarbazepine The risk or severity of sedation can be increased when Metoclopramide is combined with Eslicarbazepine.
Belinostat Injection Belinostat Injection The metabolism of Metoclopramide can be increased when combined with Belinostat.
Testosterone Injection Testosterone Injection Testosterone may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Oritavancin Injection Oritavancin Injection The metabolism of Metoclopramide can be decreased when combined with Oritavancin.
Hydrocodone Hydrocodone The risk or severity of serotonin syndrome can be increased when Hydrocodone is combined with Metoclopramide.
Suvorexant Suvorexant The risk or severity of sedation can be increased when Suvorexant is combined with Metoclopramide.
Edoxaban Edoxaban Metoclopramide may decrease the excretion rate of Edoxaban which could result in a higher serum level.
Peginterferon Beta-1a Injection Peginterferon Beta-1a Injection The metabolism of Metoclopramide can be decreased when combined with Peginterferon beta-1a.
Methamphetamine Methamphetamine The risk or severity of sedation can be increased when Metoclopramide is combined with Metamfetamine.
Tasimelteon Tasimelteon The risk or severity of sedation can be increased when Metoclopramide is combined with Tasimelteon.
Pirfenidone Pirfenidone The metabolism of Pirfenidone can be decreased when combined with Metoclopramide.
Secukinumab Injection Secukinumab Injection The metabolism of Metoclopramide can be increased when combined with Secukinumab.
Risperidone Injection Risperidone Injection The risk or severity of adverse effects can be increased when Metoclopramide is combined with Risperidone.
Insulin Human Inhalation Insulin Human Inhalation The therapeutic efficacy of Metoclopramide can be increased when used in combination with Insulin human.
Lenvatinib Lenvatinib The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Lenvatinib.
Naloxegol Naloxegol The metabolism of Metoclopramide can be decreased when combined with Naloxegol.
Panobinostat Panobinostat The metabolism of Panobinostat can be decreased when combined with Metoclopramide.
Haloperidol Injection Haloperidol Injection The risk or severity of adverse effects can be increased when Metoclopramide is combined with Haloperidol.
Ivabradine Ivabradine The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Ivabradine.
Amiloride Amiloride Amiloride may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.
Macitentan Macitentan Metoclopramide may decrease the excretion rate of Macitentan which could result in a higher serum level.
Flibanserin Flibanserin The risk or severity of sedation can be increased when Metoclopramide is combined with Flibanserin.
Rolapitant Rolapitant The metabolism of Metoclopramide can be decreased when combined with Rolapitant.
Prednisolone Prednisolone The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Prednisolone.
Brexpiprazole Brexpiprazole The risk or severity of adverse effects can be increased when Metoclopramide is combined with Brexpiprazole.
Ziprasidone Injection Ziprasidone Injection The risk or severity of adverse effects can be increased when Metoclopramide is combined with Ziprasidone.
Cariprazine Cariprazine The risk or severity of adverse effects can be increased when Metoclopramide is combined with Cariprazine.
Penicillin G Procaine Injection Penicillin G Procaine Injection Metoclopramide may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.
Eluxadoline Eluxadoline The therapeutic efficacy of Eluxadoline can be increased when used in combination with Metoclopramide.
Insulin Degludec (rDNA Origin) Injection Insulin Degludec (rDNA Origin) Injection The therapeutic efficacy of Metoclopramide can be increased when used in combination with Insulin degludec.
Trabectedin Injection Trabectedin Injection The metabolism of Trabectedin can be decreased when combined with Metoclopramide.
Osimertinib Osimertinib The serum concentration of Metoclopramide can be decreased when it is combined with Osimertinib.
Ixazomib Ixazomib Metoclopramide may decrease the excretion rate of Ixazomib which could result in a higher serum level.
Lesinurad Lesinurad Metoclopramide may decrease the excretion rate of Lesinurad which could result in a higher serum level.
Amphotericin B Liposomal Injection Amphotericin B Liposomal Injection Amphotericin B may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Dexamethasone Injection Dexamethasone Injection The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Dexamethasone.
Brivaracetam Injection Brivaracetam Injection The risk or severity of sedation can be increased when Metoclopramide is combined with Brivaracetam.
Cobicistat Cobicistat The metabolism of Metoclopramide can be decreased when combined with Cobicistat.
Pimavanserin Pimavanserin The risk or severity of adverse effects can be increased when Metoclopramide is combined with Pimavanserin.
Obeticholic Acid Obeticholic Acid The metabolism of Metoclopramide can be decreased when combined with Obeticholic acid.
Diphenhydramine Injection Diphenhydramine Injection The risk or severity of sedation can be increased when Metoclopramide is combined with Diphenhydramine.
Furosemide Injection Furosemide Injection Furosemide may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.
Rucaparib Rucaparib The metabolism of Metoclopramide can be decreased when combined with Rucaparib.
Lixisenatide Injection Lixisenatide Injection Metoclopramide may decrease the excretion rate of Lixisenatide which could result in a higher serum level.
Ribociclib Ribociclib The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Ribociclib.
Parathyroid Hormone Injection Parathyroid Hormone Injection The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Metoclopramide.
Doxepin (Insomnia) Doxepin (Insomnia) The risk or severity of sedation can be increased when Metoclopramide is combined with Doxepin.
Deutetrabenazine Deutetrabenazine The risk or severity of adverse effects can be increased when Metoclopramide is combined with Deutetrabenazine.
Valbenazine Valbenazine The metabolism of Valbenazine can be decreased when combined with Metoclopramide.
Deflazacort Deflazacort The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Deflazacort.
Safinamide Safinamide The risk or severity of sedation can be increased when Metoclopramide is combined with Safinamide.
Naldemedine Naldemedine Metoclopramide may decrease the excretion rate of Naldemedine which could result in a higher serum level.
Midostaurin Midostaurin The metabolism of Metoclopramide can be decreased when combined with Midostaurin.
Abaloparatide Injection Abaloparatide Injection The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Metoclopramide.
Enasidenib Enasidenib The metabolism of Enasidenib can be decreased when combined with Metoclopramide.
Benznidazole Benznidazole Metoclopramide may decrease the excretion rate of Benznidazole which could result in a higher serum level.
Delafloxacin Delafloxacin The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Delafloxacin.
Letermovir Letermovir The metabolism of Letermovir can be decreased when combined with Metoclopramide.
Tetrabenazine Tetrabenazine The risk or severity of adverse effects can be increased when Metoclopramide is combined with Tetrabenazine.
Ertugliflozin Ertugliflozin Ertugliflozin may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.
Buprenorphine Injection Buprenorphine Injection The therapeutic efficacy of Buprenorphine can be decreased when used in combination with Metoclopramide.
Apalutamide Apalutamide Metoclopramide may decrease the excretion rate of Apalutamide which could result in a higher serum level.
Penicillamine Penicillamine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Penicillamine is combined with Metoclopramide.
Baricitinib Baricitinib Metoclopramide may decrease the excretion rate of Baricitinib which could result in a higher serum level.
Lofexidine Lofexidine The risk or severity of sedation can be increased when Metoclopramide is combined with Lofexidine.
Plazomicin Injection Plazomicin Injection Metoclopramide may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Eliglustat Eliglustat The metabolism of Metoclopramide can be decreased when combined with Eliglustat.
Encorafenib Encorafenib The metabolism of Encorafenib can be decreased when combined with Metoclopramide.
Binimetinib Binimetinib The metabolism of Binimetinib can be decreased when combined with Metoclopramide.
Ivosidenib Ivosidenib The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Ivosidenib.
Elagolix Elagolix The metabolism of Elagolix can be decreased when combined with Metoclopramide.
Tafenoquine Tafenoquine The metabolism of Tafenoquine can be decreased when combined with Metoclopramide.
Cannabidiol Cannabidiol The risk or severity of sedation can be increased when Metoclopramide is combined with Cannabidiol.
Dacomitinib Dacomitinib The metabolism of Metoclopramide can be decreased when combined with Dacomitinib.
Stiripentol Stiripentol The risk or severity of sedation can be increased when Metoclopramide is combined with Stiripentol.
Gilteritinib Gilteritinib The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Gilteritinib.
Glasdegib Glasdegib The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Glasdegib.
Paclitaxel (with albumin) Injection Paclitaxel (with albumin) Injection The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Paclitaxel is combined with Metoclopramide.
Rifamycin Rifamycin The metabolism of Metoclopramide can be decreased when combined with Rifamycin.
Prucalopride Prucalopride Metoclopramide may decrease the excretion rate of Prucalopride which could result in a higher serum level.
Emapalumab-lzsg Injection Emapalumab-lzsg Injection The metabolism of Metoclopramide can be increased when combined with Emapalumab.
Acyclovir Ophthalmic Acyclovir Ophthalmic Acyclovir may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Brexanolone Injection Brexanolone Injection The risk or severity of sedation can be increased when Metoclopramide is combined with Brexanolone.
Cladribine Cladribine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Metoclopramide.
Solriamfetol Solriamfetol The risk or severity of sedation can be increased when Metoclopramide is combined with Solriamfetol.
Triclabendazole Triclabendazole The metabolism of Triclabendazole can be decreased when combined with Metoclopramide.
Entrectinib Entrectinib The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Entrectinib.
Istradefylline Istradefylline The metabolism of Istradefylline can be decreased when combined with Metoclopramide.
Pitolisant Pitolisant The serum concentration of Metoclopramide can be decreased when it is combined with Pitolisant.
Fedratinib Fedratinib The metabolism of Metoclopramide can be decreased when combined with Fedratinib.
Lefamulin Lefamulin Lefamulin may increase the QTc-prolonging activities of Metoclopramide.
Phenytoin Injection Phenytoin Injection The risk or severity of sedation can be increased when Phenytoin is combined with Metoclopramide.
Fosphenytoin Injection Fosphenytoin Injection The risk or severity of sedation can be increased when Fosphenytoin is combined with Metoclopramide.
Lumateperone Lumateperone The risk or severity of adverse effects can be increased when Metoclopramide is combined with Lumateperone.
Lasmiditan Lasmiditan The risk or severity of sedation can be increased when Metoclopramide is combined with Lasmiditan.
Cenobamate Cenobamate The serum concentration of Metoclopramide can be decreased when it is combined with Cenobamate.
Selumetinib Selumetinib The metabolism of Selumetinib can be decreased when combined with Metoclopramide.
Tucatinib Tucatinib The metabolism of Tucatinib can be decreased when combined with Metoclopramide.
Capmatinib Capmatinib The metabolism of Metoclopramide can be decreased when combined with Capmatinib.
Lemborexant Lemborexant The risk or severity of sedation can be increased when Metoclopramide is combined with Lemborexant.
Fenfluramine Fenfluramine The risk or severity of sedation can be increased when Fenfluramine is combined with Metoclopramide.
Fostemsavir Fostemsavir The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Fostemsavir.
Octreotide Octreotide The risk or severity of QTc prolongation can be increased when Octreotide is combined with Metoclopramide.
Opicapone Opicapone The therapeutic efficacy of Opicapone can be decreased when used in combination with Metoclopramide.
Satralizumab-mwge Injection Satralizumab-mwge Injection The serum concentration of Metoclopramide can be decreased when it is combined with Satralizumab.
Relugolix Relugolix The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Relugolix.
Progestin-Only (drospirenone) Oral Contraceptives Progestin-Only (drospirenone) Oral Contraceptives Drospirenone may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.
Viloxazine Viloxazine The risk or severity of sedation can be increased when Metoclopramide is combined with Viloxazine.
Tobramycin Injection Tobramycin Injection Tobramycin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Theophylline Theophylline The metabolism of Theophylline can be decreased when combined with Metoclopramide.
Fenoprofen Fenoprofen Fenoprofen may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Indomethacin Indomethacin Indomethacin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Mefenamic Acid Mefenamic Acid Mefenamic acid may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Naproxen Naproxen Naproxen may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Tolmetin Tolmetin Tolmetin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Sulindac Sulindac Sulindac may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Trazodone Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Metoclopramide.
Isotretinoin Isotretinoin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Isotretinoin is combined with Metoclopramide.
Sucralfate Sucralfate Sucralfate may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Hydroxyurea Hydroxyurea The metabolism of Metoclopramide can be decreased when combined with Hydroxyurea.
Floxuridine Floxuridine Floxuridine may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Phenobarbital Phenobarbital The risk or severity of sedation can be increased when Metoclopramide is combined with Phenobarbital.
Metaxalone Metaxalone The risk or severity of sedation can be increased when Metaxalone is combined with Metoclopramide.
Methotrexate Injection Methotrexate Injection Methotrexate may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Levorphanol Levorphanol The therapeutic efficacy of Levorphanol can be decreased when used in combination with Metoclopramide.
Primidone Primidone The risk or severity of sedation can be increased when Metoclopramide is combined with Primidone.
Methsuximide Methsuximide The risk or severity of sedation can be increased when Metoclopramide is combined with Methsuximide.
Diethylpropion Diethylpropion The risk or severity of sedation can be increased when Diethylpropion is combined with Metoclopramide.
Chlorpromazine Chlorpromazine The risk or severity of adverse effects can be increased when Metoclopramide is combined with Chlorpromazine.
Diazepam Diazepam The risk or severity of sedation can be increased when Diazepam is combined with Metoclopramide.
Oxazepam Oxazepam The risk or severity of sedation can be increased when Oxazepam is combined with Metoclopramide.
Flurazepam Flurazepam The risk or severity of sedation can be increased when Flurazepam is combined with Metoclopramide.
Clorazepate Clorazepate The risk or severity of sedation can be increased when Clorazepic acid is combined with Metoclopramide.
Lorazepam Lorazepam The risk or severity of sedation can be increased when Lorazepam is combined with Metoclopramide.
Carmustine Carmustine The metabolism of Metoclopramide can be decreased when combined with Carmustine.
Amantadine Amantadine The therapeutic efficacy of Amantadine can be decreased when used in combination with Metoclopramide.
Codeine Codeine The therapeutic efficacy of Codeine can be decreased when used in combination with Metoclopramide.
Meprobamate Meprobamate The risk or severity of sedation can be increased when Metoclopramide is combined with Meprobamate.
Chlordiazepoxide Chlordiazepoxide The risk or severity of sedation can be increased when Metoclopramide is combined with Chlordiazepoxide.
Bromocriptine Bromocriptine The risk or severity of sedation can be increased when Metoclopramide is combined with Bromocriptine.
Tranylcypromine Tranylcypromine The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Metoclopramide.
Phenelzine Phenelzine The risk or severity of adverse effects can be increased when Phenelzine is combined with Metoclopramide.
Procarbazine Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Metoclopramide.
Ergoloid Mesylates Ergoloid Mesylates The risk or severity of sedation can be increased when Ergoloid mesylate is combined with Metoclopramide.
Tetracycline Tetracycline Tetracycline may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Minocycline Minocycline The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Metoclopramide.
Prochlorperazine Prochlorperazine The risk or severity of adverse effects can be increased when Metoclopramide is combined with Prochlorperazine.
Thioridazine Thioridazine The risk or severity of adverse effects can be increased when Metoclopramide is combined with Thioridazine.
Trifluoperazine Trifluoperazine The risk or severity of adverse effects can be increased when Metoclopramide is combined with Trifluoperazine.
Bleomycin Bleomycin Bleomycin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Dapsone Dapsone The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Metoclopramide.
Sulfadiazine Sulfadiazine The risk or severity of methemoglobinemia can be increased when Sulfadiazine is combined with Metoclopramide.
Oxycodone Oxycodone The therapeutic efficacy of Oxycodone can be decreased when used in combination with Metoclopramide.
Methadone Methadone The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Methadone.
Oxybutynin Oxybutynin The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Metoclopramide.
Benztropine Benztropine The risk or severity of adverse effects can be increased when Metoclopramide is combined with Benzatropine.
Maprotiline Maprotiline The risk or severity of sedation can be increased when Maprotiline is combined with Metoclopramide.
Ibuprofen Ibuprofen Ibuprofen may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Trihexyphenidyl Trihexyphenidyl The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Metoclopramide.
Orphenadrine Orphenadrine The risk or severity of sedation can be increased when Metoclopramide is combined with Orphenadrine.
Perphenazine Perphenazine The risk or severity of adverse effects can be increased when Metoclopramide is combined with Perphenazine.
Azathioprine Azathioprine The metabolism of Metoclopramide can be decreased when combined with Azathioprine.
Fluphenazine Fluphenazine The risk or severity of adverse effects can be increased when Metoclopramide is combined with Fluphenazine.
Phentermine Phentermine The risk or severity of serotonin syndrome can be increased when Phentermine is combined with Metoclopramide.
Methylphenidate Methylphenidate Methylphenidate may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Amoxapine Amoxapine The risk or severity of adverse effects can be increased when Metoclopramide is combined with Amoxapine.
Sulfasalazine Sulfasalazine The risk or severity of methemoglobinemia can be increased when Sulfasalazine is combined with Metoclopramide.
Hydrocortisone Hydrocortisone The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Hydrocortisone.
Doxorubicin Doxorubicin The metabolism of Metoclopramide can be decreased when combined with Doxorubicin.
Cytarabine Cytarabine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Metoclopramide.
Phenazopyridine Phenazopyridine The risk or severity of methemoglobinemia can be increased when Metoclopramide is combined with Phenazopyridine.
Carbamazepine Carbamazepine The risk or severity of sedation can be increased when Metoclopramide is combined with Carbamazepine.
Molindone Molindone The risk or severity of adverse effects can be increased when Metoclopramide is combined with Molindone.
Methyldopa Methyldopa The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Methyldopa is combined with Metoclopramide.
Clonidine Clonidine The risk or severity of sedation can be increased when Metoclopramide is combined with Clonidine.
Hydralazine Hydralazine Metoclopramide may decrease the excretion rate of Hydralazine which could result in a higher serum level.
Cimetidine Cimetidine The metabolism of Metoclopramide can be decreased when combined with Cimetidine.
Gentamicin Injection Gentamicin Injection Gentamicin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Warfarin Warfarin Warfarin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Clonazepam Clonazepam The risk or severity of sedation can be increased when Clonazepam is combined with Metoclopramide.
Loperamide Loperamide The metabolism of Loperamide can be decreased when combined with Metoclopramide.
Promethazine Promethazine The risk or severity of adverse effects can be increased when Metoclopramide is combined with Promethazine.
Meclofenamate Meclofenamate Meclofenamic acid may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Nitrofurantoin Nitrofurantoin The risk or severity of methemoglobinemia can be increased when Nitrofurantoin is combined with Metoclopramide.
Griseofulvin Griseofulvin The metabolism of Metoclopramide can be increased when combined with Griseofulvin.
Digoxin Digoxin The serum concentration of Digoxin can be decreased when it is combined with Metoclopramide.
Loxapine Loxapine The risk or severity of adverse effects can be increased when Metoclopramide is combined with Loxapine.
Chloroquine Chloroquine The metabolism of Metoclopramide can be decreased when combined with Chloroquine.
Quinine Quinine The risk or severity of sedation can be increased when Quinine is combined with Metoclopramide.
Ethosuximide Ethosuximide The risk or severity of sedation can be increased when Ethosuximide is combined with Metoclopramide.
Triamterene Triamterene Triamterene may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Chlorothiazide Chlorothiazide Chlorothiazide may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.
Chlorthalidone Chlorthalidone Chlorthalidone may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.
Metolazone Metolazone Metolazone may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.
Isosorbide Isosorbide Isosorbide may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.
Secobarbital Secobarbital The risk or severity of sedation can be increased when Metoclopramide is combined with Secobarbital.
Desipramine Desipramine The risk or severity of sedation can be increased when Metoclopramide is combined with Desipramine.
Amitriptyline Amitriptyline The metabolism of Amitriptyline can be decreased when combined with Metoclopramide.
Imipramine Imipramine The risk or severity of sedation can be increased when Metoclopramide is combined with Imipramine.
Probenecid Probenecid Probenecid may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Quinidine Quinidine The therapeutic efficacy of Quinidine can be decreased when used in combination with Metoclopramide.
Procainamide Procainamide The metabolism of Procainamide can be decreased when combined with Metoclopramide.
Isoniazid Isoniazid The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Isoniazid is combined with Metoclopramide.
Pyrazinamide Pyrazinamide Pyrazinamide may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Rifampin Rifampin The metabolism of Metoclopramide can be increased when combined with Rifampicin.
Disopyramide Disopyramide The therapeutic efficacy of Disopyramide can be decreased when used in combination with Metoclopramide.
Valproic Acid Valproic Acid The risk or severity of sedation can be increased when Metoclopramide is combined with Valproic acid.
Tamoxifen Tamoxifen The metabolism of Metoclopramide can be decreased when combined with Tamoxifen.
Butabarbital Butabarbital The risk or severity of sedation can be increased when Metoclopramide is combined with Butabarbital.
Levothyroxine Levothyroxine The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Metoclopramide.
Liothyronine Liothyronine The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Liothyronine.
Methimazole Methimazole The metabolism of Metoclopramide can be decreased when combined with Methimazole.
Propylthiouracil Propylthiouracil The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Metoclopramide.
Chlorpropamide Chlorpropamide Chlorpropamide may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Tolbutamide Tolbutamide Tolbutamide may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Tolazamide Tolazamide Tolazamide may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Dextromethorphan Dextromethorphan The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Dextromethorphan.
Cyclobenzaprine Cyclobenzaprine The risk or severity of sedation can be increased when Metoclopramide is combined with Cyclobenzaprine.
Niacin Niacin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Niacin is combined with Metoclopramide.
Baclofen Baclofen The risk or severity of sedation can be increased when Baclofen is combined with Metoclopramide.
Doxylamine Doxylamine The risk or severity of sedation can be increased when Metoclopramide is combined with Doxylamine.
Cyproheptadine Cyproheptadine The risk or severity of sedation can be increased when Metoclopramide is combined with Cyproheptadine.
Clemastine Clemastine The risk or severity of sedation can be increased when Metoclopramide is combined with Clemastine.
Chlorpheniramine Chlorpheniramine The risk or severity of sedation can be increased when Chlorpheniramine is combined with Metoclopramide.
Brompheniramine Brompheniramine The risk or severity of sedation can be increased when Dexbrompheniramine is combined with Metoclopramide.
Meclizine Meclizine The risk or severity of sedation can be increased when Metoclopramide is combined with Meclizine.
Ethambutol Ethambutol Ethambutol may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Methyclothiazide Methyclothiazide Methyclothiazide may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.
Hydrochlorothiazide Hydrochlorothiazide Hydrochlorothiazide may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Dantrolene Dantrolene The risk or severity of sedation can be increased when Metoclopramide is combined with Dantrolene.
Chlorzoxazone Chlorzoxazone The risk or severity of sedation can be increased when Metoclopramide is combined with Chlorzoxazone.
Carisoprodol Carisoprodol The risk or severity of sedation can be increased when Metoclopramide is combined with Carisoprodol.
Methocarbamol Methocarbamol The risk or severity of sedation can be increased when Metoclopramide is combined with Methocarbamol.
Pyridoxine Pyridoxine Pyridoxine may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Folic Acid Folic Acid Folic acid may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Disulfiram Disulfiram The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Metoclopramide.
Propranolol (Cardiovascular) Propranolol (Cardiovascular) The metabolism of Propranolol can be decreased when combined with Metoclopramide.
Pseudoephedrine Pseudoephedrine The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Metoclopramide.
Nortriptyline Nortriptyline The risk or severity of sedation can be increased when Metoclopramide is combined with Nortriptyline.
Spironolactone Spironolactone Spironolactone may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.
Amphotericin B Injection Amphotericin B Injection Amphotericin B may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Phytonadione Phytonadione Phylloquinone may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Amikacin Injection Amikacin Injection Amikacin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Nadolol Nadolol The metabolism of Nadolol can be decreased when combined with Metoclopramide.
Butorphanol Injection Butorphanol Injection The therapeutic efficacy of Butorphanol can be decreased when used in combination with Metoclopramide.
Nalbuphine Injection Nalbuphine Injection The therapeutic efficacy of Nalbuphine can be decreased when used in combination with Metoclopramide.
Allopurinol Allopurinol Allopurinol may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Oxytocin Injection Oxytocin Injection The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Metoclopramide.
Trimethobenzamide Trimethobenzamide The risk or severity of sedation can be increased when Metoclopramide is combined with Trimethobenzamide.
Flavoxate Flavoxate The therapeutic efficacy of Flavoxate can be decreased when used in combination with Metoclopramide.
Papaverine Papaverine The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Papaverine.
Fluorouracil Injection Fluorouracil Injection The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Fluorouracil.
Colchicine Colchicine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Metoclopramide is combined with Colchicine.
Cefaclor Cefaclor Cefaclor may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Cefadroxil Cefadroxil Cefadroxil may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Cefazolin Injection Cefazolin Injection Cefazolin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Cephalexin Cephalexin Cephalexin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Cefoxitin Injection Cefoxitin Injection Cefoxitin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Dacarbazine Dacarbazine The metabolism of Metoclopramide can be decreased when combined with Dacarbazine.
Acetazolamide Acetazolamide The risk or severity of sedation can be increased when Acetazolamide is combined with Metoclopramide.
Cefotaxime Injection Cefotaxime Injection Cefotaxime may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Calcitonin Salmon Injection Calcitonin Salmon Injection The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Salmon calcitonin.
Ketoconazole Ketoconazole The metabolism of Metoclopramide can be decreased when combined with Ketoconazole.
Pyrantel Pyrantel The risk or severity of sedation can be increased when Metoclopramide is combined with Pyrantel.
Vincristine Injection Vincristine Injection The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Vincristine is combined with Metoclopramide.
Captopril Captopril The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Captopril is combined with Metoclopramide.
Dipyridamole Dipyridamole The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Dipyridamole.
Vinblastine Vinblastine The metabolism of Metoclopramide can be decreased when combined with Vinblastine.
Bethanechol Bethanechol The risk or severity of adverse effects can be increased when Metoclopramide is combined with Bethanechol.
Ethacrynic Acid Ethacrynic Acid Etacrynic acid may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Colistimethate Injection Colistimethate Injection Colistimethate may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Metoprolol Metoprolol The metabolism of Metoclopramide can be decreased when combined with Metoprolol.
Hydroxyzine Hydroxyzine The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Metoclopramide.
Thiothixene Thiothixene The risk or severity of adverse effects can be increased when Metoclopramide is combined with Thiothixene.
Aspirin Aspirin Acetylsalicylic acid may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Salsalate Salsalate Salsalate may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Alprazolam Alprazolam The risk or severity of sedation can be increased when Alprazolam is combined with Metoclopramide.
Temazepam Temazepam The risk or severity of sedation can be increased when Temazepam is combined with Metoclopramide.
Triazolam Triazolam The risk or severity of sedation can be increased when Triazolam is combined with Metoclopramide.
Dicyclomine Dicyclomine The therapeutic efficacy of Dicyclomine can be decreased when used in combination with Metoclopramide.
Hyoscyamine Hyoscyamine The therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Metoclopramide.
Propantheline Propantheline The therapeutic efficacy of Propantheline can be decreased when used in combination with Metoclopramide.
Trimethoprim Trimethoprim The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Metoclopramide.
Diltiazem Diltiazem The metabolism of Diltiazem can be decreased when combined with Metoclopramide.
Nifedipine Nifedipine The metabolism of Nifedipine can be decreased when combined with Metoclopramide.
Timolol Timolol The metabolism of Timolol can be decreased when combined with Metoclopramide.
Verapamil Verapamil The metabolism of Metoclopramide can be decreased when combined with Verapamil.
Atenolol Atenolol The metabolism of Atenolol can be decreased when combined with Metoclopramide.
Pindolol Pindolol The risk or severity of sedation can be increased when Metoclopramide is combined with Pindolol.
Cisplatin Injection Cisplatin Injection Metoclopramide may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Diflunisal Diflunisal Diflunisal may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Piroxicam Piroxicam Piroxicam may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Bumetanide Bumetanide The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Bumetanide is combined with Metoclopramide.
Streptozocin Streptozocin The metabolism of Metoclopramide can be increased when combined with Streptozocin.
Etoposide Etoposide The metabolism of Metoclopramide can be decreased when combined with Etoposide.
Glipizide Glipizide Glipizide may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Indapamide Indapamide Indapamide may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.
Amoxicillin Amoxicillin Amoxicillin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Nafcillin Injection Nafcillin Injection The metabolism of Metoclopramide can be increased when combined with Nafcillin.
Oxacillin Injection Oxacillin Injection Oxacillin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Pentoxifylline Pentoxifylline The metabolism of Metoclopramide can be decreased when combined with Pentoxifylline.
Pentamidine Injection Pentamidine Injection The metabolism of Pentamidine can be decreased when combined with Metoclopramide.
Ceftriaxone Injection Ceftriaxone Injection Ceftriaxone may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Labetalol Labetalol Labetalol may increase the bradycardic activities of Metoclopramide.
Auranofin Auranofin Auranofin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Leuprolide Injection Leuprolide Injection The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Leuprolide.
Gemfibrozil Gemfibrozil The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Metoclopramide is combined with Gemfibrozil.
Guanabenz Guanabenz The metabolism of Metoclopramide can be decreased when combined with Guanabenz.
Dipivefrin Ophthalmic Dipivefrin Ophthalmic Adefovir dipivoxil may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Ceftazidime Injection Ceftazidime Injection Ceftazidime may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Ketoprofen Ketoprofen Ketoprofen may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Cefotetan Injection Cefotetan Injection Cefotetan may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Pimozide Pimozide The risk or severity of adverse effects can be increased when Metoclopramide is combined with Pimozide.
Enalapril Enalapril The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Enalapril is combined with Metoclopramide.
Flurbiprofen Flurbiprofen Flurbiprofen may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Amiodarone Amiodarone The metabolism of Metoclopramide can be decreased when combined with Amiodarone.
Aztreonam Injection Aztreonam Injection Aztreonam may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Buspirone Buspirone The metabolism of Buspirone can be decreased when combined with Metoclopramide.
Lovastatin Lovastatin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lovastatin is combined with Metoclopramide.
Ciprofloxacin Ciprofloxacin The metabolism of Ciprofloxacin can be decreased when combined with Metoclopramide.
Mesalamine Mesalamine Mesalazine may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Diclofenac Diclofenac Diclofenac may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Fluoxetine Fluoxetine The risk or severity of sedation can be increased when Metoclopramide is combined with Fluoxetine.
Nimodipine Nimodipine The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Nimodipine.
Interferon Alfa-2b Injection Interferon Alfa-2b Injection The metabolism of Metoclopramide can be decreased when combined with Interferon alfa-2b.
Clozapine Clozapine The risk or severity of adverse effects can be increased when Metoclopramide is combined with Clozapine.
Estazolam Estazolam The risk or severity of sedation can be increased when Estazolam is combined with Metoclopramide.
Idarubicin Idarubicin The metabolism of Idarubicin can be decreased when combined with Metoclopramide.
Ofloxacin Ofloxacin The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Ofloxacin.
Didanosine Didanosine Didanosine may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Pentostatin Injection Pentostatin Injection Pentostatin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Clarithromycin Clarithromycin The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Clarithromycin.
Etodolac Etodolac Etodolac may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Felodipine Felodipine The metabolism of Metoclopramide can be decreased when combined with Felodipine.
Fosinopril Fosinopril Fosinopril may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Nabumetone Nabumetone Nabumetone may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Pravastatin Pravastatin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pravastatin is combined with Metoclopramide.
Simvastatin Simvastatin The metabolism of Simvastatin can be decreased when combined with Metoclopramide.
Itraconazole Itraconazole The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Metoclopramide.
Lisinopril Lisinopril Lisinopril may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Oxaprozin Oxaprozin Oxaprozin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Atovaquone Atovaquone Metoclopramide can cause a decrease in the absorption of Atovaquone resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sotalol Sotalol The metabolism of Sotalol can be decreased when combined with Metoclopramide.
Bisoprolol Bisoprolol Bisoprolol may increase the bradycardic activities of Metoclopramide.
Zolpidem Zolpidem The risk or severity of sedation can be increased when Metoclopramide is combined with Zolpidem.
Doxazosin Doxazosin The metabolism of Doxazosin can be decreased when combined with Metoclopramide.
Isradipine Isradipine The risk or severity of QTc prolongation can be increased when Isradipine is combined with Metoclopramide.
Omeprazole Omeprazole The metabolism of Metoclopramide can be increased when combined with Omeprazole.
Cisapride Cisapride The risk or severity of sedation can be increased when Metoclopramide is combined with Cisapride.
Gabapentin Gabapentin The risk or severity of sedation can be increased when Metoclopramide is combined with Gabapentin.
Fluvastatin Fluvastatin The metabolism of Fluvastatin can be decreased when combined with Metoclopramide.
Venlafaxine Venlafaxine The risk or severity of adverse effects can be increased when Metoclopramide is combined with Venlafaxine.
Nizatidine Nizatidine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nizatidine is combined with Metoclopramide.
Stavudine Stavudine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Stavudine is combined with Metoclopramide.
Fluvoxamine Fluvoxamine The risk or severity of sedation can be increased when Metoclopramide is combined with Fluvoxamine.
Nefazodone Nefazodone The risk or severity of adverse effects can be increased when Metoclopramide is combined with Nefazodone.
Lamotrigine Lamotrigine The risk or severity of sedation can be increased when Metoclopramide is combined with Lamotrigine.
Losartan Losartan The risk or severity of QTc prolongation can be increased when Losartan is combined with Metoclopramide.
Valacyclovir Valacyclovir Valaciclovir may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Tramadol Tramadol The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Metoclopramide.
Vinorelbine Injection Vinorelbine Injection The metabolism of Metoclopramide can be decreased when combined with Vinorelbine.
Carboplatin Injection Carboplatin Injection Carboplatin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Moexipril Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Metoclopramide.
Lansoprazole Lansoprazole The metabolism of Metoclopramide can be decreased when combined with Lansoprazole.
Ifosfamide Injection Ifosfamide Injection The risk or severity of methemoglobinemia can be increased when Ifosfamide is combined with Metoclopramide.
Nicardipine Nicardipine The therapeutic efficacy of Nicardipine can be decreased when used in combination with Metoclopramide.
Bupropion Bupropion The risk or severity of sedation can be increased when Bupropion is combined with Metoclopramide.
Ticlopidine Ticlopidine The metabolism of Metoclopramide can be decreased when combined with Ticlopidine.
Saquinavir Saquinavir The risk or severity of QTc prolongation can be increased when Saquinavir is combined with Metoclopramide.
Metformin Metformin Metformin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Nisoldipine Nisoldipine Nisoldipine may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Lamivudine Lamivudine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lamivudine is combined with Metoclopramide.
Riluzole Riluzole The risk or severity of sedation can be increased when Riluzole is combined with Metoclopramide.
Acarbose Acarbose Acarbose may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Gemcitabine Injection Gemcitabine Injection Gemcitabine may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Indinavir Indinavir The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Indinavir is combined with Metoclopramide.
Ritonavir Ritonavir The serum concentration of Metoclopramide can be increased when it is combined with Ritonavir.
Docetaxel Injection Docetaxel Injection The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Metoclopramide is combined with Docetaxel.
Cidofovir Injection Cidofovir Injection Cidofovir may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Meropenem Injection Meropenem Injection Meropenem may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Clomipramine Clomipramine The risk or severity of sedation can be increased when Metoclopramide is combined with Clomipramine.
Zafirlukast Zafirlukast The metabolism of Metoclopramide can be decreased when combined with Zafirlukast.
Fosfomycin Fosfomycin Fosfomycin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Mirtazapine Mirtazapine Metoclopramide may increase the serotonergic activities of Mirtazapine.
Topiramate Topiramate The risk or severity of sedation can be increased when Topiramate is combined with Metoclopramide.
Zileuton Zileuton The metabolism of Metoclopramide can be decreased when combined with Zileuton.
Insulin Lispro Injection Insulin Lispro Injection The therapeutic efficacy of Metoclopramide can be increased when used in combination with Insulin lispro.
Pramipexole Pramipexole The therapeutic efficacy of Pramipexole can be decreased when used in combination with Metoclopramide.
Donepezil Donepezil The risk or severity of sedation can be increased when Metoclopramide is combined with Donepezil.
Nelfinavir Nelfinavir The metabolism of Metoclopramide can be decreased when combined with Nelfinavir.
Azithromycin Azithromycin The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Azithromycin.
Carvedilol Carvedilol The metabolism of Carvedilol can be decreased when combined with Metoclopramide.
Nilutamide Nilutamide Nilutamide may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Flutamide Flutamide The risk or severity of methemoglobinemia can be increased when Flutamide is combined with Metoclopramide.
Selegiline Selegiline The risk or severity of sedation can be increased when Metoclopramide is combined with Selegiline.
Bicalutamide Bicalutamide The metabolism of Metoclopramide can be decreased when combined with Bicalutamide.
Sertraline Sertraline The risk or severity of sedation can be increased when Metoclopramide is combined with Sertraline.
Propafenone Propafenone The metabolism of Metoclopramide can be decreased when combined with Propafenone.
Letrozole Letrozole The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Letrozole is combined with Metoclopramide.
Tamsulosin Tamsulosin The metabolism of Tamsulosin can be decreased when combined with Metoclopramide.
Ropinirole Ropinirole The therapeutic efficacy of Ropinirole can be decreased when used in combination with Metoclopramide.
Quetiapine Quetiapine The risk or severity of adverse effects can be increased when Metoclopramide is combined with Quetiapine.
Cefepime Injection Cefepime Injection Cefepime may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Cefprozil Cefprozil Cefprozil may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Cefpodoxime Cefpodoxime Cefpodoxime may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Cetirizine Cetirizine The risk or severity of sedation can be increased when Cetirizine is combined with Metoclopramide.
Paroxetine Paroxetine The risk or severity of sedation can be increased when Metoclopramide is combined with Paroxetine.
Tolcapone Tolcapone The risk or severity of sedation can be increased when Metoclopramide is combined with Tolcapone.
Citalopram Citalopram The risk or severity of sedation can be increased when Metoclopramide is combined with Citalopram.
Capecitabine Capecitabine Capecitabine may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Efavirenz Efavirenz The risk or severity of sedation can be increased when Metoclopramide is combined with Efavirenz.
Abacavir Abacavir Abacavir may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Sildenafil Sildenafil The metabolism of Sildenafil can be decreased when combined with Metoclopramide.
Celecoxib Celecoxib The metabolism of Metoclopramide can be decreased when combined with Celecoxib.
Rosiglitazone Rosiglitazone The metabolism of Metoclopramide can be decreased when combined with Rosiglitazone.
Tolterodine Tolterodine The therapeutic efficacy of Tolterodine can be decreased when used in combination with Metoclopramide.
Thalidomide Thalidomide The risk or severity of sedation can be increased when Metoclopramide is combined with Thalidomide.
Oseltamivir Oseltamivir Oseltamivir may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Balsalazide Balsalazide Balsalazide may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Nateglinide Nateglinide The metabolism of Nateglinide can be decreased when combined with Metoclopramide.
Galantamine Galantamine The metabolism of Galantamine can be decreased when combined with Metoclopramide.
Levetiracetam Levetiracetam The risk or severity of sedation can be increased when Levetiracetam is combined with Metoclopramide.
Rabeprazole Rabeprazole The metabolism of Metoclopramide can be increased when combined with Rabeprazole.
Terbinafine Terbinafine The metabolism of Metoclopramide can be decreased when combined with Terbinafine.

Content provided by: AHFS® Patient Medication Information™. © Copyright, 2021. The American Society of Health-System Pharmacists